Starpharma Gets U.S. Grant for HIV and Genital Herpes Trial
February 16, 2007
Australia's Starpharma Holdings Ltd. said Tuesday it has received U.S. grant money to continue testing its HIV and genital herpes prevention drug. The funding from the National Institute of Allergy and Infectious Diseases and the National Institute of Child Health and Human Development will allow the biotechnology company to expand clinical trials of VivaGel in sexually active women. VivaGel is currently being studied in 60-100 women in San Francisco and Kenya. The drug will now be tested in 40 women ages 18-40 in Puerto Rico and Florida.
Australian Associated Press
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.